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Abstract
Background: Renal impairment (RI) is common in multiple myeloma (MM) and is associated with poor survival.
This study reports the associations between renal function and disease characteristics including serum free light
chain (FLC) level at diagnosis in patients with MM.
Methods: Using data from the Medical Research Council Myeloma IX trial, a multicentre, randomized, open-label,
phase III and factorial-design trial, we assessed the relationships between renal function, demographic, and disease
characteristics, including serum FLC levels, in 1595 newly diagnosed MM patients. Multivariable linear regression was
utilised to identify factors that were associated with renal function at diagnosis. A receiver operating characteristic
curve (ROC) was used to identify the optimal threshold for serum FLC level at diagnosis to predict severe RI.
Results: 52.8% of patients had an estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73 m2 (no RI), 37.3% an
eGFR 30–59 ml/min/1.73 m2 (mild to moderate RI), and 9.8% an eGFR < 30 ml/min/1.73 m2 (severe RI). In a
multivariable analysis, factors independently and negatively associated with eGFR at diagnosis were: higher serum FLC
level, female gender, and older age. Elevated serum FLC level at diagnosis, irrespective of the paraprotein type, was
strongly associated with severe RI. Receiver operating characteristic curve analysis showed a serum FLC level of >
800 mg/L as the optimal cut-off associated with severe RI (area under curve 0.86, 95% confidence interval 0.77–0.84).
Conclusion: There was a strong relationship between higher serum FLC levels at diagnosis and the severity of RI that
was irrespective of the paraprotein type. We report an increased risk of severe RI in patients presenting with serum FLC
levels above 800 mg/L at diagnosis.
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Background
Renal impairment (RI), as defined by an estimated glomeru-
lar filtration rate (eGFR) of less than 60 ml/min/1.73m2, is
present in up to 50% of patients with multiple myeloma
(MM) and is associated with a poor prognosis [1, 2]. Renal
impairment in MM can be multi-factorial; long-standing RI
can be attributed to age-related co-morbidities such as
hypertension and diabetes mellitus and is largely irreversible
[3, 4]. Acute kidney injury (AKI) can be secondary to con-
current infections, dehydration, hypercalcaemia and use of
nephrotoxic drugs and is potentially reversible with timely
supportive care. The commonest cause of severe RI at diag-
nosis (estimated glomerular filtration rate (eGFR) < 30 ml/
min/1.73m2) is through nephrotoxicity of the secreted im-
munoglobulin free light chain (FLC); this can be potentially
reversed by the rapid lowering of the involved FLC with
effective anti-myeloma therapy [5–7].
Up to one in five patients with MM have severe RI at
diagnosis, this is ten-fold the prevalence of severe RI in
an age- and gender-matched population from which
MM arises [8, 9]. Approximately 4% of patients have RI
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that requires dialysis treatment [10]. Patients with MM
and severe RI have a risk of death that is at least
two-times higher than patients with MM and normal
renal function [11].
Renal biopsy series from patients with MM have been
restricted to individuals with severe RI, often requiring
dialysis, and up to 90% of patients in these series have
myeloma cast nephropathy (MCN) [6]. Myeloma cast
nephropathy occurs because in some patients the FLC
secreted by the neoplastic plasma cells are both at a high
level and are nephrotoxic. Renal biopsies are rarely car-
ried out in patients who do not have severe RI. It is
hence not known what proportion of the mild to moder-
ate RI in MM at diagnosis is attributed to nephrotoxicity
of the secreted FLC, to other myeloma-related causes of
renal damage or to the longstanding RI that develops
due to other unrelated comorbidities. Outlining the rela-
tionship between the serum FLC level and renal function
is important, as it has the potential to provide a mechan-
istic basis for the development of RI which may in turn
direct future changes in treatment in MM based on the
FLC levels and renal function at presentation.
In this study, we assessed the relationship between serum
FLC levels and renal function across all stages of RI, except
for patients receiving or likely to require dialysis, and ana-
lysed for a threshold level in serum above which there is a
greater likelihood of FLC induced nephrotoxicity in patients
with MM. We utilised the Medical Research Council
(MRC) Myeloma IX trial dataset and included patient
demographics and disease parameters, with a focus on
paraprotein types and serum FLC levels at diagnosis, and
renal function as measured by eGFR.
Methods
The MRC Myeloma IX trial was a multicentre, random-
ized, open-label, phase-III, and factorial-design trial con-
ducted in the United Kingdom (International Standard
Randomised Controlled Trial Number 68454111). Trial
protocol details have been published previously [12–15].
In brief, patients aged 18 years or older with symptom-
atic new MM were eligible to participate in the study.
Exclusion criteria included pregnancy, asymptomatic
MM, solitary bone plasmacytoma or extramedullary
plasmacytoma, previous or concurrent active malignan-
cies, and presence of severe AKI unresponsive to up to
72-h of rehydration, characterised by a serum or plasma
creatinine more than 500 μmol/L, a urine output less
than 400 ml/day, or a requirement for dialysis. A multi-
centre research ethics committee and local ethics com-
mittees approved the protocol and all patients gave
written informed consent in accordance with the Declar-
ation of Helsinki.
All patients recruited in the intensive and non-intensive
treatment arms of the MRC Myeloma IX trial were
eligible to participate in this study if blood samples had
been sent for central laboratory analysis at entry to the
trial. The two induction regimens: oral cyclophosphamide,
thalidomide, and dexamethasone (CTD) treatment were
compared with infusional cyclophosphamide, vincristine,
doxorubicin, and dexamethasone (CVAD) in patients on
intensive treatment arm. Patients in the non-intensive
treatment arm were randomised to receive either melpha-
lan and prednisolone versus attenuated CTD. The variables
that were measured at diagnosis included: age, gender,
serum creatinine (Roche®), paraprotein type (Sebia®), para-
protein level, and serum FLC level (Freelite® assays from
The Binding Site Ltd., Birmingham, UK). The eGFR was
calculated using the Modification of Diet in Renal Disease
(MDRD) formula: eGFR (ml/min/1.73 m2) = 186 x (Serum
creatinine / 88.4)-1.154 x (Age)-0.203 x (0.742 if female gen-
der) x (1.210 if black ethnicity). Patients were divided into
three categories based on their eGFR at diagnosis; these
categories were based on those used in clinical practice for
the classification of chronic kidney disease (CKD): no RI
(eGFR ≥60 ml/min/1.73 m2), mild to moderate RI (eGFR
30–59 ml/min/1.73 m2) and severe RI (eGFR < 30 ml/min/
1.73 m2). Renal biopsy data was not collected as part of the
MRC Myeloma IX study protocol; hence results of biopsy
findings if performed for any patient recruited in the study
were unavailable for analysis.
Statistical analysis was performed using SPSS® for
Windows, version 21.0 (SPSS Inc., Chicago, IL) and
Graph Pad Prism 5.0 (GraphPad Software Inc., San
Diego, CA). Categorical variables were summarised as
frequencies and percentages. Comparisons for categor-
ical variables among different groups were made with
the chi-square test and Fisher’s exact test where appro-
priate. Continuous variables were expressed as mean
and standard deviation (SD) if the data were normally
distributed or median with interquartile range (IQR) for
non-normally distributed data. Kruskal-Wallis test was
used to compare differences in age, involved kappa FLC
level, involved lambda FLC level, involved FLC level as
per paraprotein type and eGFR at diagnosis by eGFR
categories. Mann-Whitney U test was used to compare
the differences in eGFR by gender and treatment arms
at diagnosis based on eGFR categories. Differences in
the involved serum FLC level at diagnosis for the two
FLC isotypes by eGFR categories were also compared by
the Mann-Whitney U test. Association between serum
FLC level categories and eGFR categories was assessed
by the chi-square test. The association between FLC
level in serum and severe RI was evaluated by the re-
ceiver operating characteristic (ROC) curve analysis. The
area under the curve (AUC) of sensitivity was plotted
against 1-specificity and was reported with a 95% confi-
dence interval (CI). ROC curve analysis was used to de-
termine the optimal cut-off point that maximized the
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threshold value with the highest specificity and sensitiv-
ity for severe RI. Spearman’s correlation coefficient (rs)
was calculated to evaluate the relationship between age
and log10 transformed FLC and eGFR. A multivariable
linear regression analysis was performed with factors
that were independently associated with eGFR at
diagnosis.
Results
Patient demographics and renal function
1966 patients with newly diagnosed symptomatic MM
were recruited in the MRC Myeloma IX trial; 1112
(56.6%) were assigned to the intensive arm and 854
(43.4%) to the non-intensive arm of the trial (Fig. 1).
Renal function from samples sent for central labora-
tory analysis at diagnosis were available in 1595 pa-
tients who were the focus of attention of this study.
Out of these 1595 patients, 907 patients were from
the intensive arm and 688 patients from the
non-intensive arm. The remaining 371 patients had
no samples sent for central laboratory analysis at
diagnosis and were excluded from analysis in this
study.
Table 1 shows the baseline patient characteristics.
There was a significant association between age at diag-
nosis and the severity of RI (P < 0.001); patients with RI
were older compared to patients with no RI. There was
no difference in median eGFR by gender in patients
presenting with mild to moderate (P = 0.49) or severe RI
(P = 0.74), however, males had a higher eGFR compared
to females in the no RI group (P = 0.006).
Overall a higher number of patients were recruited
in the intensive arm compared to the non-intensive
treatment arm, this was more evident in patients
presenting with no RI at diagnosis compared to those
who presented with mild to moderate RI or severe
RI (P < 0.001). Patients entering the intensive arm
with no RI had a higher eGFR at diagnosis compared
to those entering the non-intensive arm with no RI
(P < 0.001). There was no significant difference in
eGFR at diagnosis between the treatment arms in pa-
tients presenting with mild to moderate RI (P = 0.86)
or severe RI (P = 0.09).
Paraprotein and FLC isotype distribution and eGFR
Overall IgG myeloma was the predominant paraprotein
type, however, the proportion of patients with light chain
only (LCO) myeloma increased with worsening eGFR
category. The median eGFR was lower for patients with
LCO myeloma and IgD myeloma compared to those
with other paraprotein types (LCO myeloma 49.0 ml/
min/1.73 m2 [IQR 28.0–80.0]; IgD myeloma 49.0 ml/
min/1.73 m2 [IQR 36.7–83.0]; IgG myeloma 62.0 ml/
min/1.73 m2 [IQR 47.0–79.0]; IgA myeloma 64.0 ml/
min/1.73 m2 [IQR 49.0–80.0]; and IgM myeloma
65.0 ml/min/1/73 m2 [IQR 60.5–84.5]) (P < 0.001). There
Fig. 1 CONSORT diagram showing patient distribution by renal function. (MRC, Medical Research Council)
Yadav et al. BMC Nephrology  (2018) 19:178 Page 3 of 8
was no significant difference in the median age of pa-
tients between the paraprotein types (P = 0.220). An in-
volved kappa FLC isotype was more common than an
involved lambda FLC. The median eGFR in patients with
an involved lambda FLC isotype (58 ml/min/1.73 m2
[IQR 42–77]) was lower at diagnosis compared to pa-
tients with an involved kappa FLC (63 ml/min/1.73 m2
[IQR 47–80]) (P = 0.008).
Serum FLC level and eGFR
There was a sequential rise in the median involved
serum FLC level by eGFR category, irrespective of the
FLC isotype. There was no significant difference in the
median involved FLC level at diagnosis between the FLC
isotypes for any of the three eGFR categories (Fig. 2).
The median involved serum FLC level for patients with
LCO myeloma and IgD myeloma was significantly
higher compared to patients with other paraprotein
types (P < 0.001) (Fig. 3), consistent with the lower eGFR
seen in these patients.
In order to study the relationship of the varying levels
of FLC in serum with renal function, we grouped
Table 1 Patient demographics at diagnosis
Variables All patients
(n-1595)
Patients with eGFR
≥60 ml/min
(n-843)
Patients with eGFR
30–59 ml/min
(n-595)
Patients with eGFR
< 30 ml/min
(n-157)
P value
Median eGFR at diagnosis (ml/min/1.73 m2) (IQR) 61 (45–79) 78 (68–92) 48 (40–54) 21 (16–25) < 0.001
Treatment arm
Intensive (%) 907 (56.9) 536 (63.6) 290 (48.7) 81 (51.6) < 0.001
Non-intensive (%) 688 (43.1) 307 (36.4) 305 (51.3) 76 (48.4)
Median age - years (IQR) 66 (58–73) 64 (57–70) 67 (60–75) 67 (60–73) < 0.001
Gender
Male (%) 959 (60.1) 531 (62.9) 342 (57.4) 86 (54.7) 0.04
Female (%) 631 (39.5) 311 (36.9) 250 (42.0) 70 (44.6)
Unknown (%) 5 (0.3) 1 (0.1) 3 (0.5) 1 (0.6)
Myeloma Type
IgG (%) 977 (61.2) 534 (63.3) 371 (62.3) 72 (45.8) < 0.001
IgA (%) 347 (21.7) 194 (23.0) 130 (21.8) 23 (14.6)
IgM (%) 9 (0.5) 8 (0.9) – 1 (0.6)
IgD (%) 30 (1.9) 13 (1.5) 12 (2.0) 5 (3.2)
LCO (%) 215 (13.5) 83 (9.8) 76 (12.8) 56 (35.7)
Non-secretory myeloma (%) 17 (1.1) 11 (1.3) 6 (1.0) –
FLC type
Kappa (%) 1029 (65.2) 568 (68.3) 373 (63.3) 88 (56.1) 0.006
Lambda (%) 549 (34.8) 264 (31.7) 216 (36.7) 69 (43.9)
Involved FLC level (mg/L)
Median Kappa FLC (IQR) 391.20
(79.51–1106.00)
224.10
(36.96–632.20)
474.60
(115.20–1427.00)
2217.00
(668.30–5424.00)
< 0.001
Median Lambda FLC (IQR) 503.00
(90.65–1848.00)
266.90
(57.11–942.10)
722.50
(151.40–2022.00)
3071.00
(1181.00–9079.00)
Fig. 2 Serum FLC level distribution by eGFR. (showing a progressive
rise in serum FLC level with worsening of eGFR category irrespective
of the FLC isotype. Data presented as box plot with whiskers and
solid line represents median)
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patients on the basis of their eGFR at diagnosis into dif-
ferent serum FLC level categories (Fig. 4). On comparing
patients with a serum FLC level < 100 mg/L with those
with a serum FLC level of 100–299 mg/L we found no
difference in the proportions that had mild to moderate
RI or severe RI (P = 0.82). For patients with a serum FLC
level of 300–499 mg/L the proportion of patients with
mild to moderate RI increased by approximately 6% and
for severe RI by approximately 4%. There was no further
significant increase in the distribution of RI in patients
with a serum FLC level of 500–799 mg/L (P = 0.94).
However, as the serum FLC level increased > 800 mg/L
there was an exponential increase in the percentage of
patients presenting with severe RI in comparison to
those with a serum FLC level < 800 mg/L (P < 0.001).
We tested the association between serum FLC level
at diagnosis and severe RI by calculating the compos-
ite score for sensitivity and specificity as determined
by the ROC curve analysis. The AUC was 0.80 (95%
CI 0.77–0.84; P < 0.001), indicating good predictive
value for an eGFR < 30 ml/min/1.73 m2 (Fig. 5). A
serum FLC level of 500 mg/L, the level recommended
by consensus for the consideration of AKI due to
MCN, was associated with a sensitivity of 84% and
specificity of 60%. However, the optimal FLC cut-off
for prediction of eGFR < 30 ml/min/1.73 m2 was
Fig. 3 Involved serum FLC level by paraprotein type. (data presented as box plot with whiskers where solid line represents median)
Fig. 4 eGFR distribution across serum FLC level categories. (depicting increase in proportion of patients presenting with severe RI as serum FLC
level at diagnosis rises above 800 mg/L)
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800 mg/L which had a sensitivity of 80% and a speci-
ficity of 70%.
Correlations and regression modeling
There were significant correlations between age (rs −
0.174; P < 0.001) and log10 transformed serum FLC level
(rs − 0.328; P < 0.001) with eGFR at diagnosis. Multivari-
able linear regression modeling incorporating all factors
that were associated with eGFR at diagnosis showed a
significant independent association with log10 trans-
formed serum FLC level, age, and female gender but not
for the paraprotein type or the FLC isotype (Table 2).
Discussion
The purpose of this study was to investigate the relation-
ship between renal function, demographic and myeloma
characteristics, with a focus on serum FLC levels, in
newly diagnosed patients with MM. Using data collected
for the MRC Myeloma IX trial, we confirm a direct rela-
tionship between the serum FLC level and the severity
of renal impairment. The risk of severe RI as defined by
an eGFR < 30 ml/min/1.73 m2 at diagnosis, only became
substantial when the involved serum FLC level was >
800 mg/L.
Renal impairment at diagnosis is an important, poten-
tially modifiable risk factor in patients with MM [16]. In
the MRC Myeloma IX trial, patients requiring dialysis or
at a high-risk of requiring dialysis were excluded from
recruitment. Despite this 47% of patients recruited in
the study had an eGFR < 60 ml/min/1.73m2.
There are no kidney biopsy series that have systematically
reported findings from newly diagnosed MM patients with
mild to moderate RI. Thus, in most patients with MM it is
not known to what proportion the mild to moderate RI at
diagnosis is attributable to a) nephrotoxicity of FLC se-
creted by the myeloma clone, b) other myeloma-related
causes of RI, and/or c) longstanding and largely irreversible
RI due to unrelated comorbidities. In this study, the pro-
portion of patients with mild to moderate RI at diagnosis
was 37.3%, which compares to a CKD prevalence of 25%
for age- and gender-matched populations from which these
MM patients were recruited [9, 17]. This is consistent with
two-thirds of the mild to moderate RI in this cohort being
of longstanding origin and unrelated to the new diagnosis
of MM. On assessing patients with mild to moderate RI for
serum FLC level at diagnosis we found mild to moderate RI
in 32.5% of patients with a serum FLC level < 100 mg/L,
31.4% with a serum FLC level 100–299 mg/L and 38.3%
with a serum FLC level 300–499 mg/L. Only at a serum
FLC level > 2146 mg/L was there a significant increment in
the proportion of patients (44.7%) with mild to moderate
RI (P < 0.001) (Fig. 4). We interpret these findings as indi-
cating that only around 12% of MM patients with mild to
moderate RI may have had RI secondary to FLC nephro-
toxicity and in the remaining patients, RI was most likely
due to other causes.
In patients with MM and severe RI at diagnosis, renal
biopsy studies have shown that the predominant lesion
in up to 90% of patients is MCN, which is a direct con-
sequence of excess monoclonal FLC production [18].
The percentage of patients presenting with severe RI in
the current study was approximately five-fold the
reported prevalence of severe RI in an age- and
gender-matched adult population [8, 9]. This is consist-
ent with most of the severe RI observed in this study be-
ing attributable to MM rather than any pre-existing
unrelated comorbidities. Also, all patients presenting
AUC - 0.806
(95% CI; 0.77 - 0.84)
Fig. 5 Receiver operating characteristic (ROC) curve testing
association between FLC level and eGFR < 30 ml/min/1.73m2. (AUC,
area under curve; CI, confidence interval)
Table 2 Factors associated with eGFR at diagnosis
Factors Multivariable linear regression
95% confidence intervals
Beta Lower Upper P value
Age −0.277 −0.478 −0.077 0.007
Log10 serum FLC level −13.305 −15.449 −11.162 < 0.001
Female gender −3.271 0.523 6.019 0.02
IgA Myeloma 0.406 −2.881 3.693 0.80
IgM Myeloma 7.802 −13.357 28.961 0.47
IgD Myeloma −0.359 −10.203 9.486 0.94
LCO Myeloma 1.855 −1.663 5.373 0.30
Kappa FLC isotype 1.198 −1.634 4.029 0.40
Intensive arm 3.136 −1.023 7.295 0.13
(Male gender, IgG myeloma, and non-intensive arm are reference variables)
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with RI at MM diagnosis were investigated and treated
for other myeloma-related causes of RI, such as dehydra-
tion and hypercalcaemia, prior to their recruitment in
the MRC Myeloma IX trial.
FLCs have differential nephrotoxicity. In studies that
have reported on MCN, the FLC level in serum associ-
ated with the lesion can range by 100-fold; conversely,
some patients have no RI despite very high levels of
FLC. The current study reinforces this observation; 19
(2.2%) of the 843 patients with no RI had levels of serum
FLC above 5000 mg/L. Animal models and some previ-
ous clinical reports also indicate that MCN can develop
in patients at far lower serum FLC levels function [19],
indicating that nephrotoxicity of FLC varies greatly be-
tween patients.
LCO myeloma in the current study was associated
with a lower eGFR compared to other paraprotein iso-
types; this was specifically related to the serum FLC level
and is not a function of the paraprotein isotype. This
finding is consistent with a previous study, which re-
ported higher urinary FLC levels in patients with LCO
myeloma compared to patients with IgG myeloma and
IgA myeloma [20]; in that study, RI was directly related
to the urinary FLC levels. IgD myeloma was found in
1.8% of patients in the current study and the association
of RI with elevated serum FLC levels at diagnosis was
present in this group of patients as well. This and the
possibility that IgD myeloma may still be diagnosed later
than other myeloma types is under investigation in a lar-
ger cohort of patients.
78.4% of patients with LCO myeloma had a serum
FLC level > 800 mg/L and 68.2% of these had RI. In
comparison, only 27.2% of patients with an intact para-
protein MM had a serum FLC > 800 mg/L and 63.2% of
these patients had RI, further illustrating that the rela-
tionship with renal function is related to the FLC level
in serum and not the paraprotein type. This finding was
also confirmed in a multivariable linear regression model
where serum FLC level was the factor with the strongest
association with eGFR; this relationship was independent
of age and gender at diagnosis.
This study has a few limitations: in 371 patients no
samples for renal function tests were sent for central la-
boratory analysis and therefore these patients had to be
excluded from this study. Also, patients receiving or at
high risk of requiring dialysis were not recruited, as a re-
sult, the association between FLC induced nephrotox-
icity and serum FLC level could not be evaluated in
dialysis patients. Renal biopsy data were not available
and hence we were unable to correlate serum FLC levels
with myeloma cast nephropathy and other renal path-
ologies. Lastly, these results are only applicable to the
Freelite® assay and have not been validated in the other
available FLC assays [21, 22].
Conclusions
In conclusion, we report a strong relationship between
higher serum FLC levels at diagnosis and the severity of
RI, with a greater sensitivity and specificity for an FLC
level > 800 mg/L with severe RI, irrespective of the para-
protein type. Further studies are now required to more
accurately evaluate the impact of the early reduction of
high serum FLC levels on RI in patients with MM, and
to assess if this is associated with better long-term renal
function and overall survival.
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